A Pilot Study of IV [intravenous] Clofarabine for Patients With Myelodysplastic Syndrome Who Have Failed 5-Azacytidine.

Trial Profile

A Pilot Study of IV [intravenous] Clofarabine for Patients With Myelodysplastic Syndrome Who Have Failed 5-Azacytidine.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2013

At a glance

  • Drugs Clofarabine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jun 2012 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 26 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top